Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kelun-Biotech Out-Licenses Second ADC Candidate to MSD in $936 Million Deal

publication date: Jul 27, 2022

Chengdu’s Kelun-Biotech out-licensed global rights to an ADC candidate aimed at solid tumors to MSD (Merck) in a deal worth up to $936 million. No further details about the candidate were released. It is the second partnership between the two companies. Earlier this year, MSD acquired worldwide rights (ex-China) to Kelun-Biotech’s TROP2 ADC in a $1.4 billion deal ($45 million upfront). The TROP2 candidate is in Phase III trials for metastatic triple-negative breast cancer and in Phase II trials for non-small cell lung cancer and advanced solid tumors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here